Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Gentian Diagnostics ASA ( (DE:6FK) ).
Gentian Diagnostics ASA reported that its chief executive officer, Matti Heinonen, has purchased 2,500 company shares at NOK 40.00 per share, increasing his direct ownership to 7,500 shares alongside 100,000 stock options. The transaction, conducted by a primary insider and disclosed under Norwegian and EU market abuse and securities regulations, signals an additional alignment of executive and shareholder interests and underscores ongoing regulatory transparency around insider dealings.
The company stated that the share purchase by the CEO has been formally notified as a PDMR transaction, as required under the EU Market Abuse Regulation Article 19. Such insider buying can be viewed by investors as a vote of confidence in Gentian’s prospects, although the transaction size is modest relative to the overall share capital, and it mainly reinforces standard governance and disclosure practices in the Norwegian market.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a Norwegian diagnostics company focused on developing and manufacturing in vitro diagnostic reagents and assays for the medical laboratory market. The company targets clinical applications where improved biomarkers can enhance diagnostic accuracy and patient management, with its shares listed on Euronext Oslo.
Average Trading Volume: 12,014
Current Market Cap: NOK832.8M
For detailed information about 6FK stock, go to TipRanks’ Stock Analysis page.